Elanco

Cochliomyia hominivorax, the New World screw-worm fly, or screw-worm for short

New World Screwworm Reaches U.S. Livestock as Elanco Activates Response Effort

New World screwworm has officially reached U.S. livestock, prompting Elanco Animal Health to activate a portfolio of treatment and prevention tools for producers, veterinarians and pet owners. As the parasite resurfaces north of the Florida Keys for the first time in more than 50 years, the company says it is working alongside federal agencies and industry partners to help contain its spread and minimize the impact on animal health, welfare and producer livelihoods. Additional information and response resources are available through USDA, FDA and Elanco’s New World screwworm information updates.

Shiba inu dog is sitting on the grass on sunny spring day and scratching his neck

Elanco Launches Befrena™ for Canine Allergic Dermatitis With Extended Itch Control

Elanco has launched Befrena™, a new anti-IL-31 monoclonal antibody injection for canine allergic and atopic dermatitis that provides itch relief within 24 hours and lasts up to eight weeks.

Elanco Raises 2026 Outlook Following Strong First-Quarter Growth

Elanco Animal Health reported double-digit revenue growth in the first quarter of 2026, driven by strong performance from companion animal products including Credelio Quattro and Zenrelia. The company also raised its full-year revenue, EBITDA and EPS guidance while improving its leverage outlook.

Elanco Sets May 6 Date for Q1 2026 Earnings Release and Conference Call

Elanco Animal Health will report its first quarter 2026 financial results on May 6, followed by a live webcast and conference call with investors and media.

Elanco posts Q4 revenue growth, raises 2026 innovation target and reaffirms multi-year outlook

Elanco reported continued underlying revenue growth in 2025 and outlined 2026 guidance calling for mid-single-digit organic revenue gains and higher profit growth as innovation scales.

dog, puppy, pet, golden retriever, doggy, animal, pup, young dog, domestic dog, canine, mammal, cute, nature, adorable, outdoors, park, portrait

Elanco Receives USDA Approval for TruCan™ Ultra B (Oral) Bordetella Vaccine for Dogs

Elanco has received USDA approval for TruCan™ Ultra B (Oral), the first ½ mL oral Bordetella bronchiseptica vaccine for dogs, designed to deliver proven protection with improved patient comfort.

Elanco Sets Date for Q4 and Full-Year 2025 Financial Results Call

Elanco Animal Health will report fourth quarter and full-year 2025 financial results on February 24, 2026, followed by a conference call with investors and media.

Elanco Receives USDA Approval for Befrena™ Monoclonal Antibody for Canine Allergic and Atopic Dermatitis

Elanco Animal Health has received U.S. Department of Agriculture (USDA) approval for Befrena™ (tirnovetmab), an anti-IL31 monoclonal antibody injection providing long-lasting relief for dogs suffering from allergic and atopic dermatitis.

Elanco Receives Full USDA Approval for Trutect Canine Parvovirus Treatment

Elanco Animal Health has received full approval from the U.S. Department of Agriculture for Trutect™ (formerly CPMA), the first and only monoclonal antibody therapy proven to treat—and now prevent—deadly canine parvovirus.

Elanco Reports Strong Q3 2025 Results and Raises Full-Year Guidance

Elanco Animal Health reported third quarter 2025 revenue of $1.14 billion, up 10% year-over-year, with 9% organic constant currency growth, driven by pet health and farm animal performance. The company raised full-year guidance and innovation revenue targets.

Topics

New World Screwworm Reaches U.S. Livestock as Elanco Activates Response Effort

Elanco Launches Befrena™ for Canine Allergic Dermatitis With Extended Itch Control

Elanco Raises 2026 Outlook Following Strong First-Quarter Growth

Elanco Sets May 6 Date for Q1 2026 Earnings Release and Conference Call

Elanco posts Q4 revenue growth, raises 2026 innovation target and reaffirms multi-year outlook

Elanco Receives USDA Approval for TruCan™ Ultra B (Oral) Bordetella Vaccine for Dogs

Elanco Sets Date for Q4 and Full-Year 2025 Financial Results Call

Elanco Receives USDA Approval for Befrena™ Monoclonal Antibody for Canine Allergic and Atopic Dermatitis

Elanco Receives Full USDA Approval for Trutect Canine Parvovirus Treatment

Elanco Reports Strong Q3 2025 Results and Raises Full-Year Guidance

Butterfly Network Becomes Cat Friendly Practice Sponsor to Advance Feline Care

Survey Finds Itchy Skin Is Draining Dogs, Owners and Veterinarians—and Current Treatments Aren’t Meeting Expectations

Veterinary Home Infusion Pioneer Forms Clinical Advisory Board as Outpatient Care Gains Momentum

Akston Reports Long-Lasting Itch Control Comparable to Cytopoint in Canine Dermatitis Study

QC Healthcare Launches With Plans to Expand Into Veterinary Telehealth and Digital Animal Health

New Report Highlights Growing Role of Regenerative Medicine in Animal Health